Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bio-Path Holdings, Inc. (BPTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.17+0.03 (+0.58%)
At close: 4:00PM EDT
5.11 -0.06 (-1.06%)
After hours: 06:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.14
Open5.20
Bid5.14 x 900
Ask5.17 x 3000
Day's Range5.10 - 5.20
52 Week Range3.12 - 24.34
Volume28,212
Avg. Volume1,151,687
Market Cap35.984M
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-2.30
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • ACCESSWIRE

    Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH)

    DALLAS, TX / ACCESSWIRE / September 20, 2021 / Bio-Path Holdings, Inc. (NASDAQ:BPTH): The full report can be accessed by clicking on the following link: http://www.

  • Zacks

    Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

    Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.

  • Benzinga

    Why Bio-Path Holdings Shares Are Surging Higher Today

    Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients," said Peter Nielsen, president an

Advertisement
Advertisement